• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Exelixis

Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks
Favicon Fierce Biotech

Exelixis plans shuttering of East Coast site, 130 layoffs

The cancer company is closing its site in King of Prussia, Pennsylvania, to focus on operations in Alameda, California.
Darren Incorvaia Aug 29, 2025 9:15am
FDA

FDA recognizes 'crossover impact' on survival in Cabometyx nod

Mar 26, 2025 11:03am
Exelixis

Exelixis shifts focus as triplet misses OS mark in kidney cancer

Feb 18, 2025 1:30pm
Cancelled

FDA cancels adcomm for Cabometyx in neuroendocrine tumors

Jan 10, 2025 9:46am
drug prices biologics drug costs IRA money cash payment co-pay

ICER calls out drugmakers over 'unsupported' price hikes

Dec 12, 2024 2:24pm
FDA

Exelixis' Cabometyx to face FDA adcomm in neuroendocrine tumors

Nov 27, 2024 11:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings